Neoantigens Market to Reach US$ 5,607.32 Million by 2034
Neoantigens are tumor specific antigens generated from genetic mutations that occur only in cancer cells, making them highly precise therapeutic targets. Their ability to trigger strong immune responses without harming normal tissues makes them central to next generation cancer immunotherapy strategies. Ongoing advancements in genomic sequencing are expanding the identification of clinically...